Neutron Activated 153Sm Sealed in Carbon Nanocapsules for in Vivo Imaging and Tumor Radiotherapy by Wang, Julie T. W. et al.
This document is the Accepted Manuscript version of a
Published Work that appeared in final form in ACS Nano,
copyright © American Chemical Society after peer review and
technical editing by the publisher. To access the final edited
and published work see:
https://dx.doi.org/10.1021/acsnano.9b04898.
 1
Neutron Activated 153Sm Sealed in Carbon 
Nanocapsules for In Vivo Imaging and Tumor 
Radiotherapy 
Julie T.-W. Wanga, Rebecca Klippsteina, Markus Martincicb, Elzbieta Pachc, Robert Feldmand, 
Martin Sefle,f, Yves Micheld, Daniel Askera, Jane K. Sosabowskig, Martin Kalbach, Tatiana Da 
Rosi, Cécilia Ménard-Moyonj, Alberto Biancoj, Ioanna Kyriakoue, Dimitris Emfietzogloue, Jean-
Claude Saccavinid, Belén Ballesterosc,*, Khuloud T. Al-Jamala,* and Gerard Tobiasb,* 
aInstitute of Pharmaceutical Science, King’s College London, London SE1 9NH, UK 
bInstitut de Ciència de Materials de Barcelona (ICMAB-CSIC), Campus UAB, 08193 Bellaterra, 
Barcelona, Spain 
cCatalan Institute of Nanoscience and Nanotechnology (ICN2), CSIC and the Barcelona Institute 
of Science and Technology, Campus UAB, 08193 Bellaterra, Barcelona, Spain 
dCis Bio International Ion Beam Applications SA, Gif sur Yvette 91192, France 
eMedical Physics Laboratory, University of Ioannina Medical School, Ioannina GR-45110, 
Greece 
 2
fFaculty of Nuclear Sciences and Physical Engineering, Czech Technical University in Prague, 
Prague 11519, Czech Republic 
gCentre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, 
London EC1M 6BQ, UK 
hJ. Heyrovsky Institute of the Physical Chemistry, Dolejskova 3, 182 23 Prague 8, Czech 
Republic 
iINSTM Unit of Trieste, Department of Chemical and Pharmaceutical Sciences, University of 
Trieste, Via L. Giorgieri 1, 34127 Trieste, Italy 
jUniversity of Strasbourg, CNRS, Immunology, Immunopathology and Therapeutic Chemistry, 










*Corresponding authors E-mail: gerard.tobias@icmab.es, khuloud.al-jamal@kcl.ac.uk, 
belen.ballesteros@icn2.cat. 
 3
ABSTRACT: Radiation therapy along with chemotherapy and surgery remain the main cancer 
treatments. Radiotherapy can be applied to patients externally (external beam radiotherapy) or 
internally (brachytherapy and radioisotope therapy).  Previously, nanoencapsulation of 
radioactive crystals within carbon nanotubes, followed by end-closing, resulted in the formation 
of nanocapsules that allowed ultrasensitive imaging in healthy mice. Herein we report on the 
preparation of nanocapsules initially sealing ‘cold’ isotopically enriched samarium (152Sm), 
which can then be activated on demand to their ‘hot’ radioactive form (153Sm) by neutron 
irradiation. The use of ‘cold’ isotopes avoids the need for radioactive facilities during the 
preparation of the nanocapsules, reduces radiation exposure to personnel, prevents the generation 
of nuclear waste and evades the time constraints imposed by the decay of radionuclides. An 
unprecedented high specific radioactivity is achieved by neutron irradiation (up to 11.37 
GBq/mg), making the ‘hot’ nanocapsules useful not only for in vivo imaging but also 
therapeutically effective against lung cancer metastases after intravenous injection. The high in 
vivo stability of the radioactive payload, selective toxicity to cancerous tissues and the elegant 
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Advances of nanomedicine in cancer diagnosis and therapy require the production of ‘small’ 
and ‘smart’ agents that can offer specific targeting, adequate detection sensitivity, efficient 
therapeutic effects and ideally favorable biocompatibility.1-5 Carbon nanotubes (CNTs) have 
been exploited as delivery systems for theranostic applications.6-10 Their unique needle-like 
structure enables efficient cell penetration.11-14 Moreover, a selected biomedically relevant 
payload can be loaded onto the CNT structure either by chemical modification of the largely 
available external surface (exohedral), or by filling their interior space (endohedral). Surface 
engineering is a more straightforward approach and has been widely investigated.15, 16 Although 
less explored, confinement of imaging and therapeutic agents into CNTs is attracting an 
increased attention.17, 18 After encapsulation, the external walls remain available to anchor 
biocompatible and/or targeting ligands. One advantage of the nanoencapsulation approach is the 
protection that the carbon coating (CNT walls) offers to the encapsulated materials from 
enzymatic degradation once exposed to biological environment. Only highly defective, oxidized, 
CNTs are degraded by enzymes.19 Apart from CNTs, a variety of materials are being employed 
for the formation of nanocapsules that shield a selected payload.20-24 In the vast majority of 
studies, release of the encapsulated cargo is necessary to achieve a therapeutic effect via the 
delivery of bioactive agents such as drugs. This is however not the case for nuclear imaging and 
targeted radiotherapy applications where departure of the encaged imaging and/or therapeutic 
radionuclides from the nanocapsule is neither required nor desired. From the library of 
nanocapsules available, the unique properties of carbon nanotubes make them unparalleled for 
the permanent sealing of radionuclides.25-28 The graphene shells that constitute the walls of the 
CNTs can perfectly separate the core from the external environment, forming impermeable 
nanocapsules when the ends of the CNTs are closed.29, 30 Having closed ends allows the removal 
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of non-encapsulated material, after the filling step, under harsh washing conditions31 and even 
the retention of gases in their interior.32 Mutual protection is therefore afforded to both biological 
systems and the nanotube cargo delivered.7 When radionuclides are sealed, the action of ionizing 
particles exerts through the walls of CNTs25, 27, 28 and it spans from micron to millimeter 
distances depending on the characteristics of the chosen isotopes. It is worth noting that the 
internal radionuclides and external moieties (biocompatible/targeting molecules) can be 
independently changed thus giving versatility to this approach. 
In current clinical cancer therapy, half of all cancer patients are treated with radiation therapy 
either alone or combined with other types of therapies. Nanotechnology strategies however have 
been mainly driven by the use of chemotherapeutic agents. Notwithstanding, there is a growing 
interest in the development of nanomaterials bearing radioisotopes, since they offer a unique 
platform not only for molecular imaging but also to enhance the radiation response of tumors 
while reducing side effects.33-36 CNTs have been shown to deliver positron/γ-radioemitters and 
alpha particles of interest for imaging and therapeutic applications. This has been mainly 
achieved via chelation of radionuclides onto the external walls37-40 although the impregnation of 
radionuclides onto highly defective CNTs, which can be regarded as mesoporous materials, has 
also been investigated by Wilson et al.41-43 As just mentioned, an attractive feature of CNTs is 
the possibility to hermetically seal radionuclides in their interior. The nanocapsule will not only 
prevent release of the chosen radionuclides into the biological milieu but also of their decay 
products, which might be of a different chemical nature and detach from the nanocarrier with the 
previously employed strategies. We have previously reported a pioneering work using 
hermetically sealed Na125I-filled and externally glycosylated single-walled CNTs (SWNT).25 
Specific tissue accumulation (lung) coupled with high in vivo stability prevented leakage of 
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radionuclide to high-affinity organs (thyroid/stomach) or excretion, and resulted in ultrasensitive 
imaging and delivery of an unprecedented radiation dose density25 Pascu et al. have recently 
given versatility to this approach and investigated the behavior of radiometal-filled (64Cu) SWNT 
in vitro and in vivo.27 In this study the ends of the CNTs were sealed using fullerenes as corks to 
prevent release of the encapsulated radioemitter.44, 45 In contrast to these previous reports, where 
‘hot’ radionuclides, in the form of Na125I or 64Cu(OAc)2, were directly filled into SWNT, 
followed by end-closing, herein, we present a novel approach by which ‘cold’ non-radioactive 
152Sm is initially sealed into the cavities of both SWNT and multi-walled CNTs (MWNT) 
leading to the formation of closed-ended 152Sm-filled carbon nanocapsules. The encapsulated and 
stable 152Sm can then be activated into therapeutically active ‘hot’ 153Sm by neutron irradiation 
through the walls of the CNTs (Figure 1a; Schematic representations comparing both strategies 
to achieve ‘hot’ nanocapsules are included in Figure S1). After neutron activation, exceptionally 
high specific activities were obtained, compared to previous works on direct encapsulation of 
radionuclides, which allowed not only in vivo nuclear imaging but also lung tumor radiotherapy. 
153Sm is an attractive radionuclide as it emits beta particles at maximum energy of 810 keV 
(suitable for cell killing), and also releases gamma energy of 103 keV (allowing clinical 
imaging).46, 47 153Sm is used clinically in the form of 153Sm-ethylene diamine tetramethylene 
phosphonate chelate (153Sm-EDTMP, Quadramet®) for palliation of bone metastases.48 It offers 
added advantages such as desirable half-life (46.3 h) and lower gamma energy over other 
therapeutic radionuclides currently being used in clinic such as iodine-131 or yttrium-90.49  
The encapsulation of ‘hot’ radionuclides into the cavity of CNTs requires a fast and safe 
manipulation of the material due to their constant decay. By using the neutron activation strategy 
(Figure 1a), both the filling and the removal of the non-encapsulated compound do not require 
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the use of radioactive facilities thus reducing radiation exposure to the personnel. It also 
alleviates the time constraints imposed by the constant decay of radionuclides since the ‘cold’ 
nanocapsules can be shelf-stored and activated by neutron irradiation on demand. Neutron 
activation of nanoparticles incorporating neutron-activatable isotopes is well documented, with 
initial studies focused on the use of fullerenes and polymeric nanoparticles.50-54 Di Pasqua et al. 
also proposed the use of inorganic mesoporous silica nanoparticles loaded with neutron-
activatable holmium-165.55, 56 Taking advantage of the porosity of the nanocarrier, this was later 
expanded to chemoradiotherapy.57 Other inorganic materials including holmium iron garnet, 
mesoporous carbon nanoparticles and graphene oxide have more recently been explored as 
holmium nanocarriers.58-60 On the other hand, neutron activation of large particles (i.e. holmium-
166 containing microspheres) has been employed in clinical trials for the treatment of liver tumor 
via intra-arterial injection leading to radioembolization.61, 62 In this work we propose the use of 
neutron irradiation of ‘cold’ isotopically enriched 152Sm sealed within carbon nanotubes. The 
activated ‘hot’ 153Sm nanocapsules allow both in vivo imaging and tumor radiotherapy. 
 
RESULTS AND DISCUSSION 
Preparation and neutron activation of 152Sm-filled nanocapsules to yield radioactive 
153Sm@CNTs. As-received CNTs were initially purified and shortened by combination of 
solution processing with strong acids followed by steam.63 High temperature molten phase 
capillary filling was employed for the encapsulation of isotopically enriched 152SmCl3 into 
SWNT and MWNT, leading to the closing of the nanotube ends on cooling29, 30 (Figure 1a).  For 
ease of nomenclature, we will refer to these nanocapsules as 152Sm@SWNT and 
152Sm@MWNT. We employed enriched samarium (152Sm) to ensure an efficient activation to the 
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clinically employed 153Sm isotope upon neutron irradiation.64 After the filling experiment, the 
excess of 152SmCl3 external to the walls of the CNTs was removed by repeated washings and 
filtration of the sample in water. The length and diameter distribution of the samples was 
determined after the filling step. The median length turned out be 199 nm for SWNT and 331 nm 
for MWNTs (see Figure S2 and Table S1 for statistical data), and the median diameters 2.1 nm 
for SWNTs and 10.7 nm for MWNTs (Figure S3, Table S2). The amount of samarium present 
was next quantitatively determined by ICP-MS. The analyses revealed ~12.3 w/w% and 17.6 
w/w% loading of 152Sm for 152Sm@SWNT and 152Sm@MWNT, respectively. The bigger cavity 
of 152Sm in MWNTs with respect to their single-walled counterparts accounts for the larger 
amount of encapsulated 152Sm. Due to the large excess of 152SmCl3 (10 mg) that was employed 
for the bulk filling of CNTs (1 mg), only a small fraction of the metal halide was encapsulated 
(ca. 2 % according to the filling yield). With the present strategy, the non-encapsulated 152SmCl3, 
dissolved during the washing steps, is recovered by filtration. This compound is an enriched non-
radioactive form of samarium which can be dried (from the collected filtrate), stored and 
employed in further filling experiments. Therefore, no samarium waste is generated in the filling 
step. 
Neutron activation is favored in radionuclide production because of its relatively simple 
process and the availability of various types of nuclear reactors. It also permits lower radiation 
exposure to the personnel since the preparation procedures such as encapsulation, purification 
and characterization can be conducted prior to irradiation. Exceptionally high specific 
radioactivities (SRA) with respect to the mass of the composite material were obtained after 96 h 
neutron irradiation of 152Sm@SWNTs (6.33 GBq/mg) and 152Sm@MWNT (11.37 GBq/mg) 
(Table 1). The SRA values are two orders of magnitude (differ by a factor of about 100) higher 
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than those previously reported for neutron irradiated nanocarriers loaded with clinically relevant 
radiotherapeutic isotopes, which are in the range of ca. 1-80 MBq/mg (Table S3).65  This is due 
to the high neutron flux and long irradiation time employed in the present study taking into 
account the amount of 152Sm loading. In fact, such high SRA are in line of those achieved by 
neutron irradiation of pure elements or their oxides for industrial applications.64  
Structural examination of the nanocapsules before (152Sm@CNT) and after 
(153Sm@CNT) neutron irradiation. Instant thin-layer chromatography (ITLC) examination was 
performed for 153Sm@SWNT and 153Sm@MWNT to evaluate whether neutron irradiation had 
caused any structural damage to the carbon nanocapsules that could result in leakage of 152Sm 
from their interior. Based on recent studies on non-enriched SmCl3 nanocapsules, over 99% of 
SmCl3 that is not sealed inside the CNTs can be easily dissolved by a short sonication (10 s) of 
the sample in water.66 Therefore, to ensure the complete dissolution of 153Sm from the inner 
cavities of those CNTs that could have undergone structural damage, a longer sonication step 
(several min) in water was performed. As shown in Table 1 and Figure S4 a remarkable amount 
of 153Sm remained sealed in the cavities of MWNT (92%) and SWNT (70%), despite the high 
neutron flux (1.6x1014 n cm-2s-1) and long neutron irradiation time employed (96 h) to achieve 
high SRA. Milder irradiation conditions are usually used to prevent/decrease degradation of the 
carrier during neutron activation. Comparison of SRA under different conditions is included in 
Table S1. The fraction of 153Sm external to the CNT walls could be either chelated prior to in 
vivo studies or washed from the sample resulting in a minimal amount of radioactive waste, 
compared to the previously employed strategy where radionuclides were directly filled into 
CNTs. The presence of several concentric graphene layers resulted in a more stable construct to 
the flux of neutrons. Therefore, although 152Sm can be activated inside both MWNT and SWNT, 
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the former turned out to be more robust for the preparation of ‘hot’ nanocapsules by neutron 
irradiation. Even higher fractions of permanently sealed 152Sm would be expected in both 
constructs by decreasing the time and flux of neutron irradiation, with the corresponding 
reduction of SRA (according to equation (1)). 
Transmission electron microscopy (TEM) allowed us to evaluate the effect of neutron 
irradiation on the 152Sm-filled CNTs. Encapsulated 152SmCl3 can be observed in the high 
resolution TEM (HRTEM) images of 152Sm@SWNT and 152Sm@MWNT before irradiation 
(Figure 1b, top panels). The filled metal halides were still present in both types of CNTs (black 
arrows) after irradiation without evident damage on the nanotube structure. It is important to note 
that the ends of the carbon nanotubes remain sealed after neutron irradiation (pointed with white 
arrows). Additional TEM images for both ‘cold’ and ‘hot’ nanocapsules are included in Figure 
S5. Structural changes of the encapsulated crystals are sometimes observed during electron 
microscopy imaging.67-72 In the present case we observed that in some cases, SmCl3 nanowires 
were fragmented into smaller crystals (Figure S6). Preservation of the payload encapsulation was 
further confirmed by high angle annular dark field (HAADF) scanning transmission electron 
microscopy (STEM) (Figure 1b, central panels). The SmCl3 filling (bright white lines) aligned 
nicely within the CNT lumen (dim grey contrast) even following irradiation also indicating the 
presence of filling material.  
Energy dispersive X-ray (EDX) spectroscopy was conducted to assess the preservation of the 
payload content upon irradiation. The presence of samarium was detected before and after 
irradiation (Figure 1b, bottom panels). Europium, the decay product of 153Sm, was not detected 
by EDX because despite the high SRA less than 1% of 152Sm nuclei underwent nuclear reaction 
to radioactive 153Sm under the employed conditions. 
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Whole body SPECT/CT imaging and tissue biodistribution of 153Sm@CNTs in normal 
mice following i.v. injection. The 153Sm@CNT suspensions underwent different dilutions with 
non-irradiated 152Sm@CNT to contain the appropriate radioactivity for the in vivo studies in 1% 
Pluronic® F-127 saline. As just discussed, stable nanocapsules sealing 70 % (SWNT) and 92 % 
(MWNT) of 153Sm were obtained. The sonication step after neutron irradiation ensures no further 
leakage of 153Sm from the nanocapsules in vivo. The fraction of 153Sm dissolved during the 
preparation of ‘hot’ nanocapsules was chelated with EDTA to ensure a fast renal clearance.73 
The pharmacokinetics and biodistribution of 153Sm@SWNT and 153Sm@MWNT up to 24 h were 
next explored by whole body SPECT/CT imaging and quantitative γ-scintigraphy (Figure 2).  
SPECT/CT imaging demonstrated that both 153Sm@CNTs showed similar biodistribution 
patterns with accumulation mostly in spleen, lung and liver within 30 min (Figure 2a). The 
uptake in these organs was retained up to 24 h post injection (period of imaging). We have 
previously observed in vivo lung accumulation of filled CNTs bearing targeting and non-
targeting groups.25, 28 This behavior has been attributed to the physical properties of CNTs within 
physiology.28 As expected, high signals were detected from kidney and bladder within 30 min 
after injection, which were attributed to the 153Sm:EDTA chelate. From quantitative γ-
scintigraphy measurements, a progressive clearance from the blood was observed for both 
153Sm@CNTs, in which most of the compounds were cleared out from circulation at 4 h post 
injection (Figure 2b). Figure 2c shows roughly 20% and 10% of injected dose (ID) were detected 
in urine in the case of 153Sm@SWNT and 153Sm@MWNT, respectively. The results correlated 
well with the ITLC findings where a higher amount of free 153Sm was detected after neutron 
irradiation in 153Sm@SWNT than in 153Sm@MWNT (Figure S4). Negligible radioactivity was 
detected in feces for both 153Sm@CNTs (< 0.5 %ID). The organ biodistribution profiles 
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established at 4 and 24 h (Figure 2d) paralleled the SPECT/CT imaging results where 
153Sm@CNTs largely accumulated in spleen and showed high uptake in lung and liver. The 
accumulation in spleen and liver increased over time while the uptake in lung at 4 h and 24 h 
remained steady. Biodistribution analyses expressed as %ID per organ are presented in Figure 
S7.   
Assessment of radiotherapeutic efficacy of 153Sm@CNTs in B16F10-Luc melanoma lung 
metastasis. Taking advantage of the prominent lung accumulation property of CNTs, the 
radiotherapeutic efficacy of 153Sm@SWNT and 153Sm@MWNT was investigated using an 
experimental B16F10-Luc melanoma lung metastatic tumor model. This syngeneic tumor model 
is characterized as highly aggressive and metastatic, and has been commonly used for evaluation 
of cancer regimens.74, 75 The luciferase-expressing feature of this cell line enabled tumor growth 
monitoring by whole body bioluminescence imaging.  
The results demonstrate that single intravenous administration of 20 MBq of 153Sm@SWNT or 
153Sm@MWNT (200 µg of CNTs per mouse) significantly delayed the tumor growth in lung 
(Figure 3). Representative bioluminescence images of untreated, 153Sm@SWNT and 
153Sm@MWNT treated mice on day 10 and day 16 post-tumor inoculation are shown in Figure 
3a and images of all mice are shown in Figure S8. From the lung tissues examined at post-
mortem (Figure 3b), distinct differences were visualized between the treatment groups. 
Metastatic melanoma nodules occupied most of the lung tissue from the untreated mice, while 
lesser number of melanoma nodules were observed in 153Sm@CNT treated mice. The number of 
tumor nodules also reflected the lung weights in which lung tissues from untreated mice weighed 
significantly heavier than 153Sm@CNT treated mice (***p<0.001).  
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Figure 3c displays the average tumor size (photons/sec) of untreated mice and mice treated 
with 153Sm@SWNT or 153Sm@MWNT over the therapy time course. Treatment responses 
started to appear on day 13 for both 153Sm@CNTs showing significant tumor reduction 
compared to the untreated group (*p < 0.05). Although similar amount of radioactivity was 
administered and both 153Sm@CNTs showed comparable % ID in lung, notably smaller tumors 
were measured in mice treated with 153Sm@SWNT compared to 153Sm@MWNT on day 16 (*p 
< 0.05). Nevertheless, both 153Sm@CNT treatments demonstrated substantial tumor growth 
suppression on day 16 (***p < 0.001, compared to control) where the therapy study terminated.  
The reasons behind this more prolonged therapeutic effect of 153Sm@SWNT are not clear, but 
there might be differences between the two 153Sm@CNTs in terms of the interaction with lung 
tissues/tumor cells which led to the differential therapeutic outcomes.   
Histological analysis was carried out on H&E (hematoxylin and eosin stain) and Neutral Red 
stained lung tissue sections at post-mortem at the end of therapy study on day 16. The lung 
sections from untreated mice showed an invasion of cancerous mass leading to the disappearance 
of healthy lung tissues and a clear reduction of alveoli number (Figure 3d, top panels). In 
contrast, in 153Sm@CNT treated mice (Figure 3d, middle and bottom panels), lung sections 
appeared healthier with the presence of fewer colonies of melanoma nodules. Zoom-in images of 
healthy and cancerous areas from each treatment groups are shown on the right panels with 
arrows indicating some trapped 153Sm@CNTs. CNTs were difficult to identify in cancerous 
regions due to the dark appearance of melanoma. Together with the bioluminescence images, it 
indicated that 153Sm@CNT therapies did not fully eradicate tumors but prevented their 
proliferation. 
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Toxicity assessments post 153Sm@CNT injection and after radiotherapy. During the 
radiotherapy period, variable whole body weight changes were observed within groups (Figure 
4a). Body weight loss seemed to occur for the 153Sm@CNT treated mice starting from day 10 
post-tumor inoculations but there is no significant difference between the groups including the 
untreated mice. The weights of major organs were measured at sacrifice. Marginal changes were 
found between most of the untreated and 153Sm@CNT treated organs, except for lungs (with 
tumors, ***p < 0.001) and spleen (***p < 0.01 or ***p < 0.001) (Figure 4b). As previously 
evidenced in Figure 3b, the aggressively growing tumors increased the weight of lung 
significantly for the untreated mice. We have previously demonstrated that cold metal-filled 
CNTs were biocompatible in vivo.76 The significant weight loss in lungs from mice treated with 
153Sm@CNTs compared to untreated mice is likely a result of reduction of tumor nodules. 
Histological assessment performed on mice treated with low dose radioactivity (200 µg 
153Sm@CNTs/mouse, 1 MBq) showed no significant histological abnormalities in the selected 
major organs (heart, lung, kidneys, liver, and spleen) sampled at 24 h post injection (Figure S9). 
This further confirms that the reduced lung weights were due to the radiotherapy effect and not 
from the CNTs per se.  
The average weight of spleen of 153Sm@CNT treated mice was reduced compared to untreated 
tumor-bearing mice. This is less likely to be general toxicity of the CNTs but a consequence of 
the high spleen uptake of 153Sm@CNTs leading to high radioactivity accumulation. Histological 
examination on spleen with profound observation of the death of splenocytes could explain the 
spleen and body weight reduction of 153Sm@CNT treated mice since the malfunction of spleen 
can debilitate the immune system (Figure 4c). No histological abnormalities were observed for 
heart, liver, and kidney. The lack of liver toxicity further supports containments of 153Sm within 
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the CNTs in vivo. For example, studies by other groups demonstrated hepatotoxicity with 
unchelated 153Sm which naturally ends up in reticuloendothelial organs such as the liver and 
spleen.48, 73 Hematological and inflammatory examinations are needed in future investigations. 
Dosimetry simulation studies. Since the developed therapeutic 153Sm@CNT nanocapsules 
achieved promising killing effect on tumor cells, a model was established to simulate the 
performed radiation therapy. Figure 5 shows the comparison between the experimental (green 
dots) and simulated tumor growth (blue lines, according to equation (2)) data of untreated mice, 
and mice treated with 153Sm@SWNT or 153Sm@MWNT. The 153Sm@CNTs were injected on 
day 8 which is the reason for the hump on the simulated curve at day 8. For both 153Sm@SWNT 
and 153Sm@MWNT the effect of irradiation was to decrease the rate of tumor growth. Despite 
the many simplifying assumptions of the model (e.g. mono-exponential uptake, washout, and 
proliferation rates), the simulations reproduced the general trend of the experimental data for 
both systems. Moreover, the simulations successfully predicted that, for the particular 
administered activity, biodistribution features and tumor cell type, the resulting dose rate was not 
high enough. The performed radiotherapy clearly decreased the rate of tumor growth; however, 
the cell killing could not dominate over cell proliferation which could lead to complete tumor 
regression. The simulations suggest that local tumor control (defined here as the eradication of 
all tumor cells with 95% probability) requires roughly 17-28 times higher administered activities 
(330 MBq for 153Sm@MWNT and 550 MBq for 153Sm@SWNT). Taking into account the 
obtained SRA values for the prepared nanocapsules, it is indeed possible to administer the 
required dose for complete eradication of cancer in vivo (ca. 30–90 µg of undiluted 
153Sm@CNT). In view of efficacy and safety, toxicity profiles using higher doses should be 
further studied. Due to radiation regulation limits, a much lower dose (20 MBq) has been 
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employed herein for the internal radiation therapy studies. Remarkably, even using such small 
doses significant delay in tumor growth has been observed. 
 
CONCLUSIONS 
The development of radiopharmaceuticals requires a simple and safe handling of raw materials 
and final products, during both the manufacturing process, at the point of care, and during the 
intermediate steps. Furthermore, radiopharmaceuticals must be chosen carefully to deliver the 
correct activity for the particular radionuclide, given its’ half-life. The current work is an original 
concept to produce highly energetic 153Sm-encapsulated CNTs via a stable intermediate 
consisting of 152Sm-filled CNT nanocapsules, that may ultimately be used in a therapeutic 
context. Preparing the CNT nanocapsules in this way enables control over the 153Sm content and 
consequently, the activity. Furthermore, it reduces the process-complexity and the amount of 
waste that would be generated if one performed the encapsulation process directly on radioactive 
isotopes. Finally, the isotopically enriched ‘cold’ nanocapsules can be stored and activated by 
neutron irradiation when needed. Neutron irradiation of ‘cold’ 152Sm-nanocapsules turned out to 
be robust, especially for MWNT with 92% retention of 153Sm. Extremely high SRA were 
obtained (6.33 GBq/mg for 153Sm@MWNTs and 11.3 GBq/mg for 153Sm@SWNTs), which 
allowed live imaging and therapy in experimental metastatic lung tumor model in mice. The 
obtained SRA are two orders of magnitude higher than those previously reported for neutron 
activated nanomaterials bearing clinically relevant radioisotopes.65 On the other hand, the 
activity of a standard dose of clinically employed yttrium-90 microspheres is 2-4 GBq.77-79, 
requiring the administration of over 100 mg (52.0 mCi in 116 mg TheraSphere®).80 Remarkably, 
this activity can be achieved with less than 1 mg of the developed nanocapsules. Dosimetry 
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modelling studies can further optimize the treatment efficacy for potential clinical applications 
and predict the dose required. The preparation of nanocapsules with enriched isotopes benefits 
from well established filling and end closing strategies, thus giving versatility in the selection of 
neutron activatable imaging and/or therapeutic isotopes.  The possibility of carrying out further 
surface functionalization on the irradiated nanocapsules can potentially result in a stable 
nanoconstruct capable of in vivo targeting, imaging, and therapy.  
 
METHODS 
Additional experimental details are included in the Supporting Information.  
Preparation of ‘cold’ nanocapsules (152Sm@CNT). Both SWNTs and MWNTs (Elicarb®) 
were initially treated to shorten the tubes, open their ends and remove carbonaceous and metallic 
(catalyst) impurities. SWNTs were exposed to a combined piranha-steam treatment, whereas 
MWNTs underwent a combined H2SO4:HNO3-steam treatment following previously reported 
protocols.63 Steam is very efficient in removing functional groups and highly defective carbon 
nanotubes.81 Enriched 152Sm2O3 (CIS-Bio International-Ion Beam Applications, France) was 
transformed to anhydrous 152SmCl3 following the protocol reported for the synthesis of 
anhydrous SmCl3 with natural isotopic distribution (non-enriched).82 The synthesized anhydrous 
152SmCl3 is highly hygroscopic and was handled under an inert atmosphere, and employed for 
filling CNTs. SWNT or MWNT and 152SmCl3 were ground together in a weight ratio 1:10 
(CNTs:152SmCl3) inside an argon filled glove box, split in smaller fractions, placed inside silica 
tubes and sealed under vacuum. The mixtures were annealed for 12 h at 900 °C (SWNT) or 1200 
°C (MWNT)  thus leading to the formation of carbon nanocapsules (closed-ended filled 
CNTs).29, 30 Removal of the non-encapsulated 152SmCl3 with 0.6 M HCl was followed by UV-
 18
Vis, until no more 152SmCl3 was detected in the washings (0.2 μm Whatman® polycarbonate 
membranes).66 The length distribution of the resulting 152Sm@SWNT and 152Sm@MWNT was 
determined from SEM images, following a previously described methodology,83 and the 
diameter distribution from TEM images. Two hundred CNTs were measured for each of the 
analyses (see SI). 
Neutron activation of 152Sm-filled CNTs to achieve ‘hot’ nanocapsules (153Sm@CNT). The 
irradiation protocol was established according to equation (1):64 
A
. σΦ
	 1 λ       (1) 
where A is the predicted activity of the radioisotope produced (Bq g-1), M is the atomic mass 
of the target element (152 g mol-1 for 152Sm), Φ is the neutron flux of the reactor (1.6x1014 n cm-
2s-1), σ is the thermal neutron activation cross-section of the target isotope (206 barns for 153Sm), 
λ is the decay constant (0.693/T1/2), (T1/2 is the half life of the target isotope, which is 46.27 h for 
153Sm) and t is the irradiation time (96 h). Vacuum sealed silica ampoules containing 30 mg of 
either 152Sm@SWNT or 152Sm@MWNT were placed in an aluminum capsule and irradiated at a 
neutron flux of 1.6x1014 n·cm-2·s-1 for 96 h in a pool-type reactor (OSIRIS, CEA Saclay, 
France). 153Sm@SWNT and 153Sm@MWNT powders were separately suspended in a volume of 
1% Pluronic® F-127 saline (0.9 % NaCl) solution at 0.5 mg/mL.  
Characterization. HAADF-STEM images were acquired at 20 kV on an FEI Magellan XHR 
Scanning Electron Microscope (SEM). HRTEM images were acquired on a FEI Tecnai G2 F20 
microscope at 200 kV. Samples were dispersed in ethanol and deposited onto lacey carbon Cu 
grids. 153Sm@CNT were imaged after the complete decay of radioactivity. EDX was carried out 
on a FEI Quanta SEM microscope equipped with an EDAX detector at 20 kV. EDX spectra were 
acquired on large areas of CNTs (> 50 m2) to obtain representative data of the composition of 
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the samples. ICP-MS analysis was carried out using an ICP-MS with a quadrupole collision cell 
(PerkinElmer Sci EX ELAN® DRC II). Samples for ICP-MS were microwave digested (800 W, 
40 min) in a 3:1 mixture of nitric:hydrogen peroxide (Suprapur® Merck KGaA, Germany). For 
ITLC, aliquots of 153Sm@SWNT and 153Sm@MWNT were spotted on TLC strips (Agilent 
Technologies, UK) and then developed in 0.1 M ammonium acetate containing 50 mM EDTA as 
a mobile phase. Strips were allowed to dry and counted quantitatively using a cyclone phosphor 
detector (Packard Biosciences, UK). 
In vivo studies. All in vivo experiments were conducted under the authority of project and 
personal licenses granted by the UK Home Office and the UKCCCR Guidelines (1998). Female 
C57BL/6 mice aged 6-8 weeks were purchased from Harlan (UK) and used for all in vivo 
studies. Mice were anaesthetized by isoflurane (IsoFlo®, Abbott Laboratorie Ltd, UK) inhalation 
and injected via a tail vein. Each injection dose contained the same amount of CNT (200 µg), 
and the necessary radioactivity (for imaging, biodistribution or therapy studies) was a by dilution 
of the 153Sm@CNT suspensions with non-irradiated 152Sm@CNT (2 mg/mL in 1% Pluronic® F-
127 saline). Injection suspensions were added with 0.1 M EDTA (one twentieth of the injection 
volume) to chelate any free 153Sm. For histological examination, collected organs were fixed in 
10% neutral buffered formalin. Harvested fixed organs were paraffin-embedded and sectioned 
for haematoxylin and eosin (H&E) or Neutral Red staining according to standard histological 
protocols at the Royal Veterinary College (UK). All stained sections were analysed using a Leica 
DM 1000 LED Microscope (Leica Microsystems, UK) coupled with a CCD digital camera 
(Qimaging, UK). 
In vivo imaging, pharmacokinetics and organ biodistribution of 153Sm@CNTs. 
Biodistribution was firstly assessed by 3D whole body SPECT/CT imaging (Nano-SPECT/CT, 
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Bioscan, USA). SPECT images were taken in 24 projections over 30-40 min using a four-head 
scanner with 1.4 mm pinhole collimators. CT scans were performed at the end of each SPECT 
acquisition. Images were reconstructed by MEDISO software (Medical Imaging Systems), and 
SPECT and CT images were merged using the InVivoScopeTM software (Bioscan, USA). The 
radioactivity of tissues, blood, urine or feces was measured by γ-scintigraphy (LKB Wallac 1282 
Compugamma, PerkinElmer). Blood (sampled from a tail vein), urine and feces were collected 
over 24 h. To assess the excretion profiles, animals had free access to water but not food. 
In vivo 153Sm@CNT radiotherapy studies on B16F10-Luc lung metastasis tumor model. 
Mice were injected with 5 x 105 B16F10-Luc cells in 0.2 mL of PBS via a tail vein to establish 
pulmonary melanoma metastases. Following tumor inoculation, in vivo quantitative 
bioluminescence imaging was performed on day 7, 10, 13 and 16 to monitor the tumor growth 
(IVIS Lumina III, Perkin-Elmer, UK). Mice were subcutaneously injected with luciferin (D-
luciferin potassium salt, Perkin-Elmer, UK) at 150 mg/kg and imaged 10 min after injection. To 
determine the radiotherapeutic action of 153Sm@CNT, B16F10-Luc tumor bearing C57BL/6 
mice were randomly divided into three groups (n = 9-10): untreated, 153Sm@SWNT and 
153Sm@MWNT. On day 8 post tumor inoculation, mice were injected with 153Sm@CNT (ca. 20 
MBq). Mice were sacrificed on day 16 post tumor inoculation, and major organs were collected. 
Tumor growth was monitored by bioluminescence imaging. The tumor growth data was 
expressed as mean ± SEM (standard error of the mean), with n denoting the number of animals.  
Dosimetry simulation. For targeted radionuclide therapy, the surviving fraction (SF) of the 
tumor cell population over time, , can be described by equation (2).84  

























where  is the radiosensitivity parameter (Gy-1),  is the extrapolated initial dose rate (Gy h-1), 
 is the radionuclide effective uptake rate (h-1),  is the radionuclide effective washout rate (h-
1) and  is the tumor cell proliferation rate (h-1). The effective rates of uptake and washout of the 
radionuclide account for both biological and physical processes and they are defined through 
 and , respectively, where  is the biological uptake half-life,  is 
the biological washout half-life, and  is the physical half-life of the radionuclide. The values 
of  and  were obtained from a fit of the experimental tumor biodistribution data for the 
percentage injected dose (% ID) using equation (3): 
     (3) 
where  is the extrapolated % ID in the tumor at time . Note that the physical half-life of 
153Sm ( ) sets a lower limit to the values of  and  which should be larger than 
. The least square fits yielded , ,  for SWNTs, and 
, ,  for MWNTs (Figure S10). 
To obtain the rate constant for tumor cell proliferation ( ), we assume (following standard 
practice) that all tumor cells in the population are proliferating. The experimental tumor growth 
data of the non-irradiated group of mice are fitted in equation (4): 
,      (4) 
where  is the number of tumor cells at . The rate constant  in equation (4) is normally 
expressed as  with  being the tumor doubling time. Fit of the experimental data by 
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The extrapolated initial dose rate in the tumor, , entering equation (2) is estimated from 
equation (5): 
,      (5) 
where  is the administered activity to the mice (20 MBq),  is obtained from equation (3), 
 is the fraction of the organ activity that is taken up by the tumor, and  is the radiation 
absorbed dose to the tumor per radionuclide decay (Gy Bq-1 s-1). For 153Sm and a tumor mass of 
0.07 g, .85 To obtain , it is assumed that the activity was distributed 
uniformly in the tumor ( ) and the lungs ( ), so
. Substituting the above parameters in equation (2), the values 
 and  are obtained for MWNTs and SWNTs, respectively. 
The radiosensitivity parameter α was determined empirically from cell survival data using the 
expression 
,      (6) 
where  is the measured surviving fraction at  and  is the dose where the linear 
and quadratic cell-kill mechanisms (of the linear-quadratic cell survival model) are equal. For 
B16F10-Luc cells, .86 Such a high value for  corresponds to an extremely 
radioresistant cell line. Thus, to a first approximation, we can assume  which is at the 
low-end of the range of values observed for the late responding tissues.87, 88 equation (6) yields 
 Gy-1. 
From the above dosimetry model we may also obtain a rough estimate of the required 
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tumor cells with 95% probability. Assuming that 70 mg of tumor contain roughly 7×107 cells 
(and all are clonogenic) the above local tumor control probability translates to the condition 
	 . 7 10  which can be achieved with 670 MBq 153Sm@SWNT and 400 MBq 
153Sm@MWNT administered activity. If we consider the (perhaps) more realistic approximation 
that only 1% of tumor cells are clonogenic (i.e.,	 	 . 7 10 ) the corresponding 
administered activity values are 550 MBq 153Sm@SWNT and 330 153Sm@MWNT.  
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Figure 1. Preparation and characterization of carbon nanocapsules. a) Schematic representation 
of the strategy employed for the preparation of ‘hot’ nanocapsules. A non-radioactive enriched 
precursor is initially encapsulated (152Sm) and it is activated into its radioactive form by neutron 
irradiation (153Sm) in the last step. The wavy lines indicate radioactivity emerging from 
radionuclides (153Sm). b) Structural characterization of Sm-filled CNTs before (‘Cold’ 
nanocapsules) and after (‘Hot’ nanocapsules) irradiation. HRTEM images are shown in the top 
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panels. Black arrows point to the SmCl3 filling, and white arrows to closed tips of carbon 
nanotubes. The crystalline structure of SmCl3 can be better appreciated on the MWNT images, 
with visible lattice fringes (parallel lines). HAADF-STEM images are shown in the middle 
panels. The bright lines correspond to the filling of SmCl3, while CNTs appear as a dim grey 











Figure 2. Whole body SPECT/CT imaging and tissue biodistribution of 153Sm@SWNT and 
153Sm@MWNT in mice up to 24 h. a) SPECT/CT imaging, b) blood circulation, c) excretion 
profiles and d) tissue biodistribution profiles. C57BL/6 mice were i.v. injected with 200 µg of 
EDTA-quenched 153Sm@SWNT or 153Sm@MWNT containing 10 MBq or ~1 MBq for 
SPECT/CT imaging or γ-scintigraphy, respectively. In excretion studies, mice were housed 
individually in metabolic cages for 24 h immediately after injection. The radioactivity in blood, 
major organs sampled at specified time points and urine/feces collected at 24 h post injection, 





Figure 3. Tumor growth delay studies in experimental metastatic lung tumor mice model after 
internal administration of radiotherapy. B16F10-Luc tumor-bearing C57BL/6 mice received a 
single i.v. injection of 153Sm@SWNT or 153Sm@MWNT (20 MBq, 200 µg) on day 8 post-tumor 
inoculation. a) Average lung weights measured on day 16 post-tumor inoculation, the 
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experimental endpoint. b) Representative whole-body images of untreated, 153Sm@SWNT and 
153Sm@MWNT treated mice captured on days 10 and 16 post-tumor inoculation. c) Tumor 
growth monitoring over time. Bioluminescence signals correspond to luciferase expressing 
B16F10 cells in the lung. d) H&E and Neutral Red stained B16F10-Luc tumor-containing lung 
tissue sections excised on day 16 (left panels). High magnification images of tumor (areas 1) and 
non-tumor (areas 2) lung tissues are shown on the right. Arrows indicate the presence of CNTs. 
Scale bars: 200 μm for H&E and Neutral Red stained sections; 5 μm for zoom-in images of areas 
1 and 2. Results are presented as mean ± S.D. (n=9-10). Significant differences were examined 
using one-way ANOVA followed by Tukey’s multiple comparison test (*p < 0.05, **p < 0.01, 
***p < 0.001). 
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Figure 4. Toxicity assessments in tumor-bearing mice treated with 153Sm@SWNT and 
153Sm@MWNT via intravenous injection. B16F10-Luc tumor-bearing C57BL/6 mice received a 
single i.v. injection of 153Sm@SWNT or 153Sm@MWNT (20 MBq, 200 µg) on day 8 post-tumor 
inoculation. a) Percentage of whole body weight changes of B16F10-Luc tumor-bearing mice 
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after radiotherapy. b) Major organ weight and c) histological examination of major organs on day 
16 post tumor inoculation. The body weight of individual mouse was measured every 3-4 days 
post tumor-inoculation. At the experimental endpoint on day 16, major organs including heart, 
kidney, liver and spleen were excised, weighed and fixed for histological examination. Tissue 
sections were stained with H&E (examine necrosis) or Neutral Red (track CNTs). Scale bars: 50 
μm. Results are presented as mean ± S.D. (n = 9-10). No statistical differences were found in % 
whole body weight changes between different treatments.  Mice treated with 153Sm@CNTs 
showed significant weight reduction in lung and spleen. Significant differences were examined 




Figure 5. Predicted and experimental relative tumor sizes as a function of time in control or 
153Sm@SWNT- and 153Sm@MWNT-treated mice. B16F10-Luc tumor-bearing C57BL/6 mice 
received a single dose i.v. injection of 153Sm@SWNT or 153Sm@MWNT (20 MBq, 200 µg) on 
day 8 post tumor inoculation or remained untreated. Green dots represent experiment data and 
blue lines are simulated results for the three groups: a) untreated control, b) 153Sm@SWNT 
treated group, and c) 153Sm@MWNT treated group. The calculated blue lines are plotted 
according to equation (2). The values of the coefficients entered in equation (2) are as follows: 
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for all three cases, the radiosensitivity parameter was =0.0068 Gy-1 and the cell doubling time 
Td equals 39.78 h which corresponds to a proliferation rate = ln(2)/Td = 0.017 h-1. Extrapolated 
initial dose rate r0, effective uptake rate m, and effective washout rate k are specific for each 
case. Specifically, for the untreated sample (a), the extrapolated initial dose rate r0 equals 0 
whereas for SWNT (b) the parameter values are: r0 = 1.872 Gy h-1, k = 0.0162 h-1, m = 2.34 h-1 
and for MWNT (c) the parameter values are r0 = 3.158 Gy h-1, k = 0.0160 h-1, m = 0.826 h-1. The 
detailed derivation of the parameter values for each case is given in the Dosimetry simulation 




Table 1. Neutron irradiation of 152Sm@SWNT and 152Sm@MWNT to achieve radioactive 
















152Sm@SWNT 12.3 96 7.77 6.33 70 
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Figure S1. Schematic representation of the strategies employed for the hermetic sealing of 
radionuclides into the cavities of carbon nanotubes (hot nanocapsules). a) Previously 
employed strategies where radionuclides (125I and 64Cu) are directly filled into carbon 
nanotubes[1]. b) Present strategy, also depicted in Fig. 1a (main text), where a non-radioactive 
enriched precursor is initially encapsulated (152Sm) and it is activated into its radioactive form by 
neutron irradiation (153Sm) in the last step. In both schematic representations, the wavy lines 
















Figure S2. Length distribution of 152Sm@CNT samples. a) Length distribution histogram and 
b) box plot analysis of SWNT; c) Length distribution histogram and d) box plot analysis of 
MWNT. 
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Figure S3. Diameter distribution of 152Sm@CNT samples. a) Diameter distribution histogram 
and b) box plot analysis of SWNT; c) Diameter distribution histogram and d) box plot analysis of 
MWNT. 
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Figure S4. ITLC analysis of 153Sm@SWNT and 153Sm@MWNT following neutron irradiation 
of 152Sm@SWNT and 152Sm@MWNT respectively. Signals at the application point represent the 
stably encapsulated radionuclides.   
 
 
Figure S5. HRTEM images of Sm-filled SWNTs before (‘Cold’ nanocapsules) and after (‘Hot’ 








Figure S6. HAADF STEM images of a 152SmCl3@SWNT showing that during electron 
microscopy observation the filling material displaces inside the SWNT. a) Initially acquired 
image and b) an image of the same area acquired after ca. 30 seconds. Displacement of the filling 






























MWNT  152Sm    96 h  1.6x1014  11.37 GBq/mg  11370.0  This work 
SWNT  152Sm    96 h  1.6x1014  6.33 GBq/mg  6330.0  This work 
C82  165Ho  1 min  4.3x1014  16.13 Ci/mg  0.6  [2] 
MCN  165Ho    10 h  5.5x1012  208 Ci/100 g  77.0  [3] 
HoIG  165Ho      0.45 h  7.0x1012  250 Ci/mg  9.3  [4] 
Silica NPs  165Ho      1 h  3.5x1012  213.6 Ci/mg  7.9  [5] 
Silica NPs  165Ho      2.2 hc  5.5x1012  129 MBq/10.7 mg  12.1   [6]  
Silica NPs  165Ho      2 h  5.5x1012  150 Ci/mg  5.6  [7] 
Silica NPs  165Ho      3 h  7.7x1012  300 Ci/mg  11.1  [7] 
AcAc  165Ho    13 min  5.5x1012  0.25 mCi/10 mg  0.9  [8] 
AcAc  165Ho      1 h  5.0×1012  600 MBq/50 mg  12.0   [9] 
PLLA  165Ho      1 h  1.1×1013  27.4 GBq/g  27.4  [10] 












Figure S7. Tissue biodistribution of 153Sm@SWNT and 153Sm@MWNT (presented as %ID 
per organ). C57/Bl6 mice were i.v. injected with 200 µg of 153Sm@SWNT or 153Sm@MWNT 
(~1 MBq). The radioactivity of major organs sampled at specified time points were measured by 
γ-scintigraphy. The results are expressed as % ID/organ and presented as mean ± S.D. (n=3-4). 
 
Figure S8. Live bioluminescence images of untreated mice or mice treated with 
153Sm@SWNT or 153Sm@MWNT. B16F10-Luc tumor-bearing mice were i.v. injected with 20 
MBq in 200 µg of 153Sm@SWNT or 153Sm@MWNT on day 8 post-tumor inoculation. 
Bioluminescence signals correspond to metabolic activity of luciferase-expressing B16F10 cells 








































Figure S9.  Histological examination of major organs from C57BL/6 mice at 24 h post 
injection of 153Sm@SWNT and 153Sm@MWNT. C57BL/6 mice were i.v. injected with 200 µg 
of 153Sm@SWNT or 153Sm@MWNT (~1 MBq). At 24 h post injection, heart, lung, kidney, liver, 
and spleen were excised and formalin-fixed, stained with H&E (for tissue necrosis) or Neutral 
Red (for CNT visualization). As a guide to the eye arrows point to some CNT aggregates. Scale 







Figure S10. Fit of the experimental biodistribution data (% ID) in the lung using equation 3 
described in the manuscript. Fitted parameters are %.ID 6160  , 
101620  h.k  1322  h.m  for 
SWNT, and %.ID 0280  , 
101600  h.k 18260  h.m  for MWNT. Experimental data are 

















Materials and Reagents: Chemical vapor deposition (CVD) Elicarb® SWNTs and MWNTs were 
supplied by Thomas Swan & Co. Ltd (UK) as a solid powder. The SWNT material also contains 
a fraction of double-walled carbon nanotubes. Enriched 152Sm2O3 were provided by CIS-Bio 
International-Ion Beam Applications (France). Hydrogen peroxide, sulphuric acid and nitric 
acids were purchased from Panreac AppliChem (Spain) for CNT pre-treatment. Instant thin layer 
chromatography paper impregnated with silica gel (ITLC-SG) was obtained from Agilent 
Technologies (UK).  Isoflurane for anesthesia was purchased from Abbott (IsoFlo®, Abbott 
Laboratorie Ltd, UK).  
 Purification and Shortening of CNTs: Both SWNTs and MWNTs were initially treated to 
shorten the tubes, open their ends and remove carbonaceous and metallic (catalyst) impurities. 
SWNTs were exposed to a combined piranha-steam treatment, whereas MWNTs underwent a 
combined H2SO4:HNO3-steam treatment following previously reported protocols.[11] 
Synthesis of 152SmCl3 from 152Sm2O3: Enriched 152Sm2O3 was transformed to anhydrous 152SmCl3 
following the protocol reported for the synthesis of anhydrous SmCl3 with natural isotopic 
distribution (non-enriched).[12] The synthesis of the anhydrous metal halide was performed by 
dissolution of the enriched metal oxide in HCl, followed by dehydration of the collected solid at 
240 °C under dynamic vacuum. The synthesized anhydrous 152SmCl3 is highly hygroscopic and 
was handled under an inert atmosphere.  
Filling of CNTs with 152SmCl3: Cut and purified SWNT (100 mg) or MWNT (200 mg) and 
152SmCl3 were ground together in a weight ratio 1:10 (CNTs:152SmCl3). The materials were 
ground using an agate mortar and pestle inside an argon filled glove box until the mixture 
presented a uniform color. The samples were split in smaller fractions, placed inside silica tubes 
and sealed under vacuum. The resulting silica ampoules were placed inside a horizontal tubular 
furnace and annealed for 12 h at 900 °C (SWNT) or 1200 °C (MWNT)  thus leading to the 
formation of carbon nanocapsules (closed-ended filled CNTs). The samples were recovered from 
the ampoules and the non-encapsulated material, external to the CNTs was dissolved and washed 
away. The removal of the external material was followed by UV-Vis spectroscopy of the 
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collected filtrates, until no more 152SmCl3 was detected in the washings.[13] Initially the filled 
nanotubes were soaked in 200 mL of water containing 0.6 M HCl. The sample was then 
collected by filtration over a 0.2 μm polycarbonate membrane. This “pre-washing” step was 
followed by washing the sample three times in 200 mL acidic water at 80 °C for 24 h under 
constant stirring each time. The sample was collected by filtration between washings. A final 
washing step was performed using 200 mL of pure water, without the addition of HCl, whilst 
keeping the rest parameters constant. The collected solid powder was dried at 80 °C overnight.  
Neutron activation of 152Sm-filled CNTs: Vacuum sealed silica ampoules containing 30 mg of 
either 152Sm@SWNT or 152Sm@MWNT were placed in an aluminum capsule, weighed down 
with a lead-weight in a pool-type reactor (OSIRIS, CEA Saclay, France) and irradiated at a 
neutron flux of 1.6x1014 n·cm-2·s-1 for 96 h. The irradiation protocol was established according to 
equation (1):[14] 
A . σΦ 	 1 λ       (1) 
where A is the predicted activity of the radioisotope produced (Bq g-1), M is the atomic mass of 
the target element (152 g mol-1 for 152Sm), Φ is the neutron flux of the reactor (1.6x1014 n cm-2s-
1), σ is the thermal neutron activation cross-section of the target isotope (206 barns for 153Sm), λ 
is the decay constant (0.693/T1/2), (T1/2 is the half life of the target isotope, which is 46.27 h for 
153Sm) and t is the irradiation time (96 h). The value of A for the given conditions can then be 
used to make a prediction of the nanotubes, by factoring in the mass of nanotubes and the 
corresponding percentage content of 152Sm that was measured before the irradiation.  
After removing the ampoules from the pool, they were allowed to cool down, removed from the 
aluminum casing, and then transferred to CIS bio International, Saclay (France) where they were 
processed in a fully sealed radioprotection hot cell. Radioactivity was measured using a dose 
calibrator (VDC 404, Veenstra Instruments, The Netherlands). The ampoules were then shattered 
and the contents (153Sm@SWNT and 153Sm@MWNT powders) were separately suspended in a 
volume of 1% Pluronic® F-127 saline (0.9 % NaCl) solution, using sonication such to produce a 
suspension with a loading of 0.5 mg/mL. The glass fragments from the broken silica ampoule 
were separated from the bulk of the suspension by sedimentation. Large aggregates of 
153Sm@CNTs were also precluded in this way. In order to transfer this product to the in vivo 
 14
facilities in vials, keeping within their local limits of activity handling, only a fraction of this 
suspension was then separated into a final vial, which was then shipped and arrived in a few 
days. On arrival, a sonication and a series of dilution steps were performed to ensure that the 
final dispersion injected in mice was physically stable and free of aggregates, as detailed in the in 
vivo section.  
Quantification of 152SmCl3 filling yields by ICP-MS: As a analytical validation measure, each 
carbon nanotube sample was subdivided into fractions of different sizes in the range of 1-15 mg, 
and was weighed three times on a pre-calibrated analytical balance. The samples were then 
added to a PTFE-TFM reactor in an Anton Paar Multiwave 3000, fitted with an 8SXF100 rotor. 
6 mL 65% Suprapur® nitric acid (Merck KGaA, Germany), and then 2 mL of 30% Suprapur® 
hydrogen peroxide (Merck KGaA, Germany) were dispensed from calibrated micropipettes and 
the microwave digestion was completed by applying 800 W for 40 minutes, with an initial ramp 
of 5 min. The contents of each reactor were then transferred to a polyproylene flask, followed by 
a series of washings with de-ionised water (ELGA Labwater PURELAB® Classic water 
purifying system; resistivity 18.2 MΩ/cm), and the volume was then made up to 25 mL. Two 
additional control solutions were prepared and analyzed. It was demonstrated that no impurities 
were introduced during this process using a “preparation blank,” consisting of all of the reagents 
except the nanotubes, that was passed through the microwave at the same time as the actual 
samples. It was also confirmed that all of the material that was added to the reactors was 
recovered by preparing a solution from the final washing. Prior to analysis by ICP-MS, all of the 
samples were filtered with a 33 mm 0.22 µm MILLEX ® GV PVDT filter.  
ICP-MS analysis was carried out at Cis Bio International using an ICP-MS with a quadrupole 
collision cell (PerkinElmer Sci EX ELAN® DRC II). The system check consisted of: a daily 
performance report using a standard reference solution of magnesium, indium, uranium, cerium 
and barium, with relative standard deviations (RSD) within 0.4 to 1.1% of the anticipated value. 
The sample sequence then consisted of triplicate injections of: a blank containing de-ionized 
water, the “preparation blank” and then the actual samples, separated by injections of de-ionized 
water. The quantification was performed using an external 152Sm calibration standard. The 
stability of the measurements was monitored by spiking each sample with an identical level of a 
rhodium standard of 5 ppb and this gave RSDs of less than 1%. The range of concentrations 
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chosen for the 152Sm calibration depended on the particular sample and covered the ranges of 
either 1 to 5 ppb or 1 to 30 ppb, and all of Pearson correlation coefficients R2 coefficients were 
greater than 0.9999. The results corresponding to the overall % 152Sm were then reported to one 
decimal place. 
Electron microscopy: HAADF-STEM images were acquired at 20 kV on an FEI Magellan XHR 
Scanning Electron Microscope (SEM) with the use of a specially adapted detector. HRTEM 
images were acquired on a FEI Tecnai G2 F20 microscope at 200 kV. Samples were dispersed in 
ethanol and deposited onto lacey carbon Cu grids. 153Sm@CNT were imaged after the complete 
decay of radioactivity.  EDX was carried out on a FEI Quanta SEM microscope equipped with 
an EDAX detector at 20 kV.  
Animals: All in vivo experiments were conducted under the authority of project and personal 
licenses granted by the UK Home Office and the UKCCCR Guidelines (1998). Female C57BL/6 
mice aged 6-8 weeks were purchased from Harlan (UK) and used for all in vivo studies. 
ITLC examination of 153Sm@CNTs: ITLC was performed to examine whether there was free 
153Sm present in the 153Sm@CNT suspensions (neutron irradiated 152Sm@CNT) prior to 
injection. Aliquots of 153Sm@SWNT and 153Sm@MWNT were spotted on TLC strips and then 
developed in 0.1 M ammonium acetate containing 50 mM EDTA as a mobile phase. Strips were 
allowed to dry and counted quantitatively using a cyclone phosphor detector (Packard 
Biosciences, UK). 
Preparation of 153Sm-CNTs for in vivo studies: The 153Sm@CNT suspensions underwent 
different dilutions to contain the appropriate radioactivity for different in vivo studies. The 
dilution was carried out by mixing the 153Sm@CNT dispersions with different amounts of non-
irradiated 152Sm@CNT suspensions (2 mg/mL in 1% Pluronic® F-127 saline). The resulting 
mixture was then sonicated for 10-15 min. Each injection dose, either for imaging, 
biodistribution or therapy studies, contained the same amount of CNT (200 µg), but possessed 
different radioactivity which are specified in their experimental sections accordingly. Injection 
suspensions were added with 0.1 M EDTA (one twentieth of the injection volume) to chelate any 
free 153Sm. 
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In vivo SPECT/CT imaging of 153Sm@CNT following i.v. injection: The biodistribution of 
153Sm@CNTs was firstly assessed by 3D whole body SPECT/CT imaging. Mice were 
anaesthetized by isoflurane inhalation during imaging. Each injection dose for 153Sm@SWNT or 
153Sm@MWNT suspensions contained approximately 10 MBq. Injection suspensions were 
added with 0.1 M EDTA (one twentieth of the injection volume) to chelate free 153Sm. 
Immediately after injection, and at 4 h and 24 h, mice were imaged using the Nano-SPECT/CT 
scanner (Bioscan, USA). SPECT images of each mouse were taken in 24 projections over 30-40 
min using a four-head scanner with 1.4 mm pinhole collimators. CT scans were performed at the 
end of each SPECT acquisition. All images were reconstructed by MEDISO software (Medical 
Imaging Systems), and SPECT and CT images were merged using the InVivoScopeTM software 
(Bioscan, USA). 
Pharmacokinetics and organ biodistribution of 153Sm@CNTs by γ-scintigraphy: Mice 
anaesthetized by isoflurane inhalation were injected with 153Sm@SWNT or 153Sm@MWNT 
suspensions via a tail vein. Each injection dose of 153Sm@SWNT or 153Sm@MWNT suspensions 
contained approximately 0.8 MBq. Blood was sampled from a tail vein at 5 min, 30 min, 4 h or 
24 h after injection. At 4 h and 24 h, mice were sacrificed and major organs were excised and 
weighed. To assess the excretion profiles, animals were housed individually in metabolic cages 
where the mice have free access to water but not food. Urine and feces were collected over 24 h 
after injection. The radioactivity of each sample (i.e. tissues, blood, urine or feces) was measured 
by γ-scintigraphy (LKB Wallac 1282 Compugamma, PerkinElmer) and the results were 
expressed as percentage injection dose per sample (% ID) or per g of sample (% ID/g). Collected 
organs were fixed in 10% neutral buffered formalin for histological examination. 
B16F10-Luc lung metastasis tumor model: Mice anaesthetized by isoflurane inhalation were 
injected with 5 x 105 B16F10-Luc cells in 0.2 mL of PBS via a tail vein to establish pulmonary 
melanoma metastases. Following tumor inoculation, in vivo quantitative bioluminescence 
imaging was performed on day 7, 10, 13 and 16 to monitor the tumor growth (IVIS Lumina III, 
Perkin-Elmer, UK). Mice under anesthesia were subcutaneously injected with luciferin (D-
luciferin potassium salt, Perkin-Elmer, UK) at 150 mg/kg and imaged 10 min after injection. 
Bioluminescence signals from regions of interests were measured using Living Image software 
(Perkin-Elmer, UK) and recorded as total flux (photons/sec). 
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In vivo 153Sm@CNT radiotherapy studies: To determine the radiotherapeutic action of 
153Sm@SWNT and 153Sm@MWNT, B16F10-Luc tumor bearing C57BL/6 mice were randomly 
divided into three groups (n = 10): untreated, 153Sm@SWNT and 153Sm@MWNT. On day 8 post 
tumor inoculation, mice were intravenously injected with 200 µg of 153Sm@SWNT or 
153Sm@MWNT suspensions containing approximately 20 MBq. Mice were sacrificed on day 16 
post tumor inoculation, and major organs including lung, liver, spleen, heart, and kidney were 
weighed and fixed in 10% neutral buffered formalin for histological examination. Tumor growth 
was monitored by bioluminescence imaging as described previously. The tumor growth data was 
expressed as mean ± SEM (standard error of the mean), with n denoting the number of animals. 
Significant differences were examined using one-way ANOVA followed by Tukey's multiple 
comparison test. *: p < 0.05; ***: p < 0.001  
Histological examination: Major organs excised from the mice in the biodistribution study (i.e. 
24 h post injection) and from the mice after 153Sm@CNT radiotherapy were subjected to 
histological examination. Harvested fixed organs were paraffin-embedded and sectioned for 
haematoxylin and eosin (H&E) or Neutral Red staining according to standard histological 
protocols at the Royal Veterinary College (UK). All stained sections were analysed using a Leica 
DM 1000 LED Microscope (Leica Microsystems, UK) coupled with a CCD digital camera 
(Qimaging, UK). 
References 
[1] a) S. Y. Hong, G. Tobias, K. T. Al-Jamal, B. Ballesteros, H. Ali-Boucetta, S. Lozano-Perez, 
P. D. Nellist, R. B. Sim, C. Finucane, S. J. Mather, M. L. H. Green, K. Kostarelos, B. G. Davis, 
Nat. Mater. 2010, 9, 485; b) H. Ge, P. J. Riss, V. Mirabello, D. G. Calatayud, S. E. Flower, R. L. 
Arrowsmith, T. D. Fryer, Y. Hong, S. Sawiak, R. M. J. Jacobs, S. W. Botchway, R. M. Tyrrell, 
T. D. James, J. S. Fossey, J. R. Dilworth, F. I. Aigbirhio, S. I. Pascu, Chem 2017, 3, 437. 
[2] D. W. Cagle, S. J. Kennel, S. Mirzadeh, J. M. Alford, L. J. Wilson, Proc. Natl. Acad. Sci. U. 
S. A. 1999, 96, 5182. 
[3] J. Kim, Z.-X. Luo, Y. Wu, X. Lu, M. Jay, Carbon 2017, 117, 92. 
[4] I. Munaweera, Y. Shi, B. Koneru, R. Saez, A. Aliev, A. J. Di Pasqua, K. J. Balkus, Mol. 
Pharm. 2015, 12, 3588. 
[5] I. Munaweera, B. Koneru, Y. Shi, A. J. D. Pasqua, J. Kenneth J. Balkus, APL Mater. 2014, 2, 
113315. 
[6] A. J. Di Pasqua, H. Yuan, Y. Chung, J. K. Kim, J. E. Huckle, C. Li, M. Sadgrove, T. H. Tran, 
M. Jay, X. Lu, J. Nucl. Med. 2013, 54, 111. 
[7] A. J. Di Pasqua, M. L. Miller, X. Lu, L. Peng, M. Jay, Inorg. Chim. Acta 2012, 393, 334. 
 18
[8] A. J. Di Pasqua, J. E. Huckle, J.-K. Kim, Y. Chung, A. Z. Wang, M. Jay, X. Lu, Small 2012, 
8, 997. 
[9] W. Bult, R. Varkevisser, F. Soulimani, P. R. Seevinck, H. de Leeuw, C. J. G. Bakker, P. R. 
Luijten, A. D. van het Schip, W. E. Hennink, J. F. W. Nijsen, Pharm. Res. 2010, 27, 2205. 
[10] H. Fessi, H. Salim, D. Barbos, Drug Dev. Ind. Pharm. 2008, 34, 796. 
[11] M. Kierkowicz, E. Pach, A. Santidrián, S. Sandoval, G. Gonçalves, E. Tobías-Rossell, M. 
Kalbáč, B. Ballesteros, G. Tobias, Carbon 2018, 139, 922. 
[12] M. Martincic, C. Frontera, E. Pach, B. Ballesteros, G. Tobias, Polyhedron 2016, 116, 116. 
[13] M. Martincic, E. Pach, B. Ballesteros, G. Tobias, Phys. Chem. Chem. Phys. 2015, 17, 
31662. 
[14] Manual for reactor produced radioisotopes, IAEA-TECDOC-1340, Vienna, Austria 2003. 
 
 
